Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 277

1.

Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.

Sanchis-Borja M, Ricordel C, Chiappa AM, Hureaux J, Odier L, Jeannin G, Descourt R, Gervais R, Monnet I, Auliac JB, Chouaïd C.

Lung Cancer. 2020 Mar 17;143:36-39. doi: 10.1016/j.lungcan.2020.03.006. [Epub ahead of print]

PMID:
32200139
2.

Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study.

Gibiot Q, Monnet I, Levy P, Brun AL, Antoine M, Chouaïd C, Cadranel J, Naccache JM.

J Clin Med. 2020 Mar 5;9(3). pii: E700. doi: 10.3390/jcm9030700.

3.

Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis.

Landre T, Des Guetz G, Vergnenegre A, Chouaid C.

Ann Oncol. 2019 Apr;30 Suppl 2:ii60. doi: 10.1093/annonc/mdz063.063. No abstract available.

4.

Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.

Girard N, Pérol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C.

Ann Oncol. 2019 Apr;30 Suppl 2:ii34. doi: 10.1093/annonc/mdz067.006. No abstract available.

5.

First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.

Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R.

Cancer Med. 2020 Feb 5. doi: 10.1002/cam4.2806. [Epub ahead of print]

6.

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.

Bylicki O, Guisier F, Monnet I, Doubre H, Gervais R, Janicot H, Perol M, Fournel P, Lamy R, Auliac JB, Chouaid C.

Medicine (Baltimore). 2020 Jan;99(3):e18726. doi: 10.1097/MD.0000000000018726.

7.

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.

Guisier F, Dubos-Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Pérol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O.

J Thorac Oncol. 2020 Apr;15(4):628-636. doi: 10.1016/j.jtho.2019.12.129. Epub 2020 Jan 13.

8.

Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.

Giaj Levra M, Cotté FE, Corre R, Calvet C, Gaudin AF, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assié JB, Chouaïd C.

Lung Cancer. 2020 Feb;140:99-106. doi: 10.1016/j.lungcan.2019.12.017. Epub 2019 Dec 31.

9.

Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy.

Dalon F, Devouassoux G, Belhassen M, Nachbaur G, Correia Da Silva C, Sail L, Jacoud F, Chouaid C, Van Ganse E.

Int J Chron Obstruct Pulmon Dis. 2019 Dec 16;14:2905-2915. doi: 10.2147/COPD.S222762. eCollection 2019.

10.

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017).

Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, Léna H, Chouaïd C, Robinet G.

Future Oncol. 2020 Feb;16(4):5-10. doi: 10.2217/fon-2019-0730. Epub 2020 Jan 2.

11.

[Evolution of the costs and management of lung cancer between 2004 and 2014].

Gadby F, Descourt R, Robinet G, Quere G, Gouva S, Roge C, Couturaud F, Chouaid C.

Rev Mal Respir. 2020 Jan;37(1):1-7. doi: 10.1016/j.rmr.2019.10.010. Epub 2019 Dec 17. French.

PMID:
31862137
12.

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.

Kissel M, Martel-Lafay I, Lequesne J, Faivre JC, Le Péchoux C, Stefan D, Barraux V, Loiseau C, Grellard JM, Danhier S, Lerouge D, Chouaid C, Gervais R, Thariat J.

BMC Cancer. 2019 Dec 19;19(1):1237. doi: 10.1186/s12885-019-6449-8.

13.

Evaluation of the Idylla system to detect the EGFRT790M mutation using extracted DNA.

Bocciarelli C, Cohen J, Pelletier R, Tran Van Nhieu J, Derman J, Favre L, Bourgogne A, Monnet I, Chouaid C, Pujals A.

Pathol Res Pract. 2020 Jan;216(1):152773. doi: 10.1016/j.prp.2019.152773. Epub 2019 Dec 2.

PMID:
31836323
14.

First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.

Landre T, Des Guetz G, Chouahnia K, Taleb C, Vergnenègre A, Chouaïd C.

J Cancer Res Clin Oncol. 2020 Feb;146(2):441-448. doi: 10.1007/s00432-019-03070-3. Epub 2019 Nov 4.

PMID:
31686247
15.

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.

Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, Baik C, Joy AA, Chouaid C, Jaime JC, Kolek V, Majem M, Roubec J, Santos ES, Chiang AC, Speranza G, Belani CP, Chiappori A, Patel MR, Czebe K, Byers L, Bahamon B, Li C, Sheldon-Waniga E, Kong EF, Williams M, Badola S, Shin H, Bedford L, Ecsedy JA, Bryant M, Jones S, Simmons J, Leonard EJ, Ullmann CD, Spigel DR; C14018 study investigators.

J Thorac Oncol. 2020 Feb;15(2):274-287. doi: 10.1016/j.jtho.2019.10.013. Epub 2019 Oct 23.

16.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG.

Clin Lung Cancer. 2020 Jan;21(1):e10-e14. doi: 10.1016/j.cllc.2019.09.007. Epub 2019 Oct 1.

PMID:
31648999
17.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C.

Lung Cancer. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010. Epub 2019 Aug 14.

PMID:
31491676
18.

Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care.

Bylicki O, Didier M, Riviere F, Margery J, Grassin F, Chouaid C.

BMJ Support Palliat Care. 2019 Dec;9(4):413-424. doi: 10.1136/bmjspcare-2019-001770. Epub 2019 Aug 31.

19.

Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66].

Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot AB, Monnet I.

Lung Cancer. 2019 Oct;136:159. doi: 10.1016/j.lungcan.2018.10.011. Epub 2019 Aug 14. No abstract available.

PMID:
31421927
20.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations.

Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21.

PMID:
31379105
21.

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.

Auliac JB, Dô P, Bayle S, Doubre H, Vinas F, Letreut J, Falchero L, Hauss PA, Thomas P, Chouaid C.

Adv Ther. 2019 Aug;36(8):2161-2166. doi: 10.1007/s12325-019-01001-9. Epub 2019 Jun 1.

22.

Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.

Auliac JB, Saboundji K, Andre M, Madelaine J, Quere G, Masson P, Vergnenegre A, Lamy R, Raymond S, Chiappa AM, Hauss PA, Fournel P, Corre R, Chouaid C.

Target Oncol. 2019 Jun;14(3):307-314. doi: 10.1007/s11523-019-00646-4.

PMID:
31119481
23.

Lung cancer survivors and employment: A systematic review.

Vayr F, Savall F, Bigay-Game L, Soulat JM, Chouaid C, Herin F.

Lung Cancer. 2019 May;131:31-39. doi: 10.1016/j.lungcan.2019.03.010. Epub 2019 Mar 11.

PMID:
31027695
24.

Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature.

Guyard A, Charpy C, Théou-Anton N, Cremades A, Grassin F, Bourgogne A, Leroy K, Pujals A, Copie-Bergman C, Chouaid C, Mansuet-Lupo A.

Transl Oncol. 2019 May;12(5):784-787. doi: 10.1016/j.tranon.2019.02.015. Epub 2019 Mar 22.

25.

LUCSO-1-French pilot study of LUng Cancer Screening with low-dose computed tomography in a smokers population exposed to Occupational lung carcinogens: study protocol.

Delva F, Laurent F, Paris C, Belacel M, Brochard P, Bylicki O, Chouaïd C, Clin B, Dewitte JD, Le Denmat V, Gehanno JF, Lacourt A, Margery J, Verdun-Esquer C, Mathoulin-Pélissier S, Pairon JC.

BMJ Open. 2019 Mar 23;9(3):e025026. doi: 10.1136/bmjopen-2018-025026.

26.

[Respiratory isolation in suspected tuberculosis with negative direct sputum examination].

Pichon J, Chouaid C, Marc E, Voiriot G.

Rev Mal Respir. 2019 Mar;36(3):396-404. doi: 10.1016/j.rmr.2018.08.025. Epub 2019 Mar 20. Review. French.

27.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

Costantini A, Fallet V, Corny J, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Brosseau S, Wislez M, Tredaniel J, Cadranel J.

Lung Cancer. 2019 Apr;130:128-134. doi: 10.1016/j.lungcan.2019.01.015. Epub 2019 Feb 14.

28.

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.

Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O'Donnell JC, Penrod JR, Daumont M, Lacoin L, McKenney A, Khovratovich M, Munro RE, Durand-Zaleski I, Johnsen SP.

Future Oncol. 2019 May;15(14):1551-1563. doi: 10.2217/fon-2019-0025. Epub 2019 Mar 11.

29.

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.

Bylicki O, Barazzutti H, Paleiron N, Margery J, Assié JB, Chouaïd C.

BioDrugs. 2019 Apr;33(2):159-171. doi: 10.1007/s40259-019-00339-4. Review.

PMID:
30825132
30.

The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database.

Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouee S, Laurendeau C, Bureau I, Gourmelen J, Chouaid C.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1477-1487. doi: 10.1016/j.jaip.2018.12.029. Epub 2019 Jan 25.

PMID:
30685573
31.

Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France.

Chouaid C, Germain N, De Pouvourville G, Aballéa S, Korchagina D, Baldwin M, Le Lay K, Luciani L, Toumi M, Devillier P.

Curr Med Res Opin. 2019 May;35(5):785-792. doi: 10.1080/03007995.2019.1574507. Epub 2019 Feb 15.

PMID:
30681007
32.

Continuity of care in general practice at cancer diagnosis (COOC-GP study): a national cohort study of 2853 patients.

Hurtaud A, Aubin M, Ferrat E, Lebreton J, Paillaud E, Audureau E, Bastuji-Garin S, Chouaid C, Boisnault P, Clerc P, Canouï-Poitrine F.

Br J Gen Pract. 2019 Feb;69(679):e88-e96. doi: 10.3399/bjgp19X700805. Epub 2019 Jan 14.

33.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

Lung Cancer. 2019 Jan;127:96-102. doi: 10.1016/j.lungcan.2018.11.037. Epub 2018 Nov 27.

PMID:
30642559
34.

Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P.

Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.

35.

Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB).

Chouaid C, Salaün M, Gounant V, Febvre M, Vergnon JM, Jouniaux V, Fournier C, Lachkar S, Hermant C, Raspaud C, Quantin X, Quiot JJ, Molard A, Dayen C, Marquette CH, Lena H, Zalcman G, Thiberville L.

PLoS One. 2019 Jan 7;14(1):e0208992. doi: 10.1371/journal.pone.0208992. eCollection 2019.

36.

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

Auliac JB, Bayle S, Vergnenegre A, Le Caer H, Falchero L, Gervais R, Doubre H, Vinas F, Marin B, Chouaid C.

Curr Oncol. 2018 Oct;25(5):e398-e402. doi: 10.3747/co.25.3945. Epub 2018 Oct 31.

37.

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.

Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C.

BMC Cancer. 2018 Oct 22;18(1):1013. doi: 10.1186/s12885-018-4958-5.

38.

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R.

Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11. Erratum in: Cancer Med. 2019 Sep;8(12):5820.

39.

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.

Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Mazières J, Colineaux H, Lepage B, Chouaid C; GFPC Investigators.

Oncology. 2018;95(6):337-343. doi: 10.1159/000489784. Epub 2018 Oct 2.

PMID:
30278447
40.

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.

Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801220. doi: 10.1183/13993003.01220-2018. Print 2018 Oct.

41.

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.

Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1159-1165. doi: 10.1080/14737140.2018.1518714. Epub 2018 Sep 17.

PMID:
30173589
42.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:310-316. doi: 10.1016/j.lungcan.2018.07.042. Epub 2018 Aug 10.

43.

Lung cancer and interstitial lung disease: a literature review.

Naccache JM, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C, Cadranel J.

J Thorac Dis. 2018 Jun;10(6):3829-3844. doi: 10.21037/jtd.2018.05.75. Review.

44.

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.

Saboundji K, Auliac JB, Pérol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaïd C.

Target Oncol. 2018 Aug;13(4):501-507. doi: 10.1007/s11523-018-0581-2.

PMID:
30039345
45.

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.

Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C.

Onco Targets Ther. 2018 Jul 16;11:4051-4064. doi: 10.2147/OTT.S154606. eCollection 2018. Review.

46.

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.

Babey H, Quéré G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum JB, Cornec D, Tison A, Chouaid C.

Expert Rev Anticancer Ther. 2018 Oct;18(10):981-989. doi: 10.1080/14737140.2018.1499468. Epub 2018 Jul 20. Review.

PMID:
29995451
47.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007. Epub 2018 Jun 9.

48.

Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach.

Boyer L, Bastuji-Garin S, Chouaid C, Housset B, Le Corvoisier P, Derumeaux G, Boczkowski J, Maitre B, Adnot S, Audureau E.

Sci Rep. 2018 Jun 5;8(1):8569. doi: 10.1038/s41598-018-26766-x.

49.

Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

Vergnenègre A, Chouaïd C.

Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):519-528. doi: 10.1080/14737167.2018.1485099. Epub 2018 Jun 14. Review.

PMID:
29869900
50.

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).

Locher C, Pourel N, Le Caer H, Berard H, Auliac JB, Monnet I, Descourt R, Vergnenègre A, Lafay IM, Greillier L, Chouaïd C.

Lung Cancer. 2018 Jul;121:25-29. doi: 10.1016/j.lungcan.2018.04.017. Epub 2018 Apr 22.

PMID:
29858022

Supplemental Content

Loading ...
Support Center